- Home
- BRNS vs DUKR Comparison
BRNS vs DUKR Comparison
Compare BRNS & DUKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$0.72
N/A
Current Price
$5.71
Company Overview
Basic Information| Metric | BRNS | DUKR |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Aerospace |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.1M | 20.1M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | BRNS | DUKR |
|---|---|---|
| Price | $0.72 | $5.71 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | 23.2K | ★ 25.8K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.51 | $6.14 |
| 52 Week High | $2.91 | $7.41 |
Technical Indicators
Market Signals| Indicator | BRNS | DUKR |
|---|---|---|
| Relative Strength Index (RSI) | 50.13 | N/A |
| Support Level | $0.65 | N/A |
| Resistance Level | $0.75 | N/A |
| Average True Range (ATR) | 0.06 | 0.00 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 32.06 | 0.00 |
Price Performance
Historical Comparison BRNS
DUKR
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.